Former US head of Leo Pharma gets board seat at Kempharm
Christopher Posner is joining the board of Kempharm, which acquired embattled biotech firm Orphazyme earlier this year.
by mikkel aabenhus hemmingsen, translated by catherine brett
Biotech firm Kempharm has made space for the former President and CEO of Leo Pharma in the US, Christopher Posner, at its board table, the firm announces in a stock exchange notification.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme CEO on sale: "It’s sad, but we tried everything"
For subscribers
